Browse News
Filter News
Found 228 articles
-
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
9/20/2023
Oxford Biomedica plc announces interim results for the six months ended 30 June 2023.
-
Postdoctoral programs in industry are often overlooked by PhD candidates but they provide certain benefits over academic positions, including better pay.
-
Otsuka Pharmaceutical to Acquire Mindset Pharma
8/31/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation
-
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
7/6/2023
Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.
-
Ora, Inc. Appoints Nate Speicher as Chief Financial Officer
6/28/2023
Ora, Inc. , the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today that Nate Speicher has been appointed Chief Financial Officer (CFO).
-
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines
6/28/2023
Alloy Therapeutics announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
-
Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder
6/22/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs,
-
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
6/9/2023
PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, is pleased to report that the US Food and Drug Administration has approved a clinical trial utilizing PharmAla’s LaNeo MDMA Investigational Medical Product capsules.
-
FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration
5/30/2023
Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration.
-
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
5/16/2023
PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules and its distribution partner, CCrest Laboratories have received an authorization to provide a number of its LaNeo MDMA capsules to a Canadian physician for treatment of a patient under Health Canada’s Special Access Program.
-
Micron Biomedical Extends Series A to $17 Million to Bring Needle-Free Drugs and Vaccines to Market
5/10/2023
Micron Biomedical announced it has secured an additional $3 million investment from J2 Ventures, bringing its total Series A funding to $17 million.
-
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
5/2/2023
Tris Pharma, Inc. today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.
-
Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
5/2/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance across its global markets.
-
Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
4/26/2023
Mindset Pharma Inc. today announced that it has filed two international patent applications under the Patent Coorperation Treaty (“PCT”) for the protection of certain of Mindset’s non-hallucinogenic novel non-tryptamine compounds known as “Family 6.”
-
Vetter Performs Extraordinarily with Six Wins in the 12th Annual CDMO Leadership Awards
3/28/2023
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), earned the esteemed 2023 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service.
-
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
3/21/2023
AION Labs and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.
-
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
3/14/2023
Mindset Pharma Inc. today announced that the Company has been made aware that Reunion Neuroscience Inc. (“Reunion”) has filed a lawsuit against Mindset in the United States District Court for the District of New Jersey asserting, among others, inventorship and co-ownership of one of Mindset’s patents, inequitable conduct, and breach of contract.
-
AION Labs Launches AI Startup for De Novo Antibody Design
2/28/2023
AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of DenovAI, the lab's second startup approved by the Israel Innovation Authority.
-
As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.
-
Astellas Announces Change of President and CEO and Management Structure
2/6/2023
Astellas Pharma Inc. announced that at a meeting of its Board of Directors, held today, approved changes of its Representative Director, President and CEO and its management structure.